Takeda Bio Begins Local Phase I, II Trials Of Lymphoma Drug
This article was originally published in PharmAsia News
Executive Summary
Takeda Bio Development Center has begun simultaneous Phase I and II trials in Japan of its brentusimab vedotin antibody for treating malignant lymphoma